At the news
? BULLISHIMPACT 8/10 8-K filed Jul 27, 2026 at 06:06 ET
Forte Biosciences (FBRX) has entered into a definitive merger agreement to be acquired by argenx (ARGX) for $77.00 per share in cash, representing a total equity value of approximately $2.2 billion. The transaction will proceed via a tender offer followed by a merger under Section 251(h) of the DGCL, with the Forte board unanimously recommending the offer. The deal provides a substantial premium to recent trading levels and is expected to close in Q3 2026, funded entirely from argenx's cash on hand, with no financing condition.
- argenx to acquire Forte Biosciences for $77.00 per share in cash, total equity value ~$2.2 billion
- Premium of approximately 86% to Forte's VWAP since reporting positive Phase 1b vitiligo data on July 9, 2026
- Transaction structured as a tender offer for a majority of shares, followed by a merger under DGCL Section 251(h)
- Forte's lead program is FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access